Board of Directors
Lauren G. Barnes (Chair)
Lauren G. Barnes (Chair)
Blueprint Medicines, Senior Vice President, Market Access
Lauren Barnes is the Senior Vice President of Market Access at Blueprint Medicines, a leading personalized medicine company focused on delivering new medicines that are targeted to the genetic driver of disease. Blueprint is focused on three distinct areas of medicine; genomically defined cancers, rare diseases and cancer immunotherapy.
Prior to joining Blueprint, Ms. Barnes spent four years at Vertex Pharmaceuticals as Vice President of Managed Markets. In this role, Ms. Barnes launched multiple therapies for the treatment of cystic fibrosis. Ms. Barnes was responsible for ensuring patient access to these therapies and was proud to see the profound impact the drugs had on patient lives.
Immediately before Vertex, Ms. Barnes spent ten years at the advisory services firm, Avalere Health, where she was the Senior Vic President of Reimbursement & Commercialization. During her time at Avalere, she provided strategic payer planning and public policy expertise to clients in the pharmaceutical and biotechnology industries to assist in the successful commercialization of their products. Earlier in her career, Ms. Barnes was Director of the Payment and Coverage Group at Amgen. Immediately prior to her time with Amgen, she worked for the Centers for Medicare & Medicaid Services in the Coverage and Analysis Group and sat on the Healthcare Common Procedure Coding System panel.
Ms. Barnes has a BA in Public Health and a MHS in Health Care Policy from Johns Hopkins University.
McKinsey & Company
Bjoern Albrecht is a partner at McKinsey & Company, a worldwide management consulting firm. He works with pharmaceutical and biotech companies, health systems, and providers on cancer-related topics. He leads the McKinsey Cancer Center, coordinating all of McKinsey’s work on cancer-related topics globally, and is also a leader in the Pharmaceuticals & Medical Products Practice in Europe. Mr. Albrecht manages the annual “McKinsey Cancer Congress Series” Satellite Symposium at the American Society of Clinical Oncology. He holds a Ph.D. in molecular, cellular, and developmental biology from The Ohio State University Comprehensive Cancer Center and a BS in biochemistry and molecular biology from the University of Hamburg.
Vertex Pharmaceuticals Inc., Executive Vice President & Chief Commercial Officer
Stuart A. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Commercial Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s sales, marketing, patient support, market research and other activities that support the approved use of Vertex’s two medicines.
Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000-person biotechnology company. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® and Nplate®. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan and emerging markets in Asia, the Middle East and Africa.
Prior to these roles, Mr. Arbuckle spent more than 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom. Mr. Arbuckle currently serves as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Health Section Governing Board for the Biotechnology Industry Organization.
AEG Global Partnerships, Vice President
Nick Baker is a Senior Vice President in the Global Partnerships division of AEG. The Global Partnerships business group, formed atop the company’s organizational structure, guides AEG’s continued development in the area of sponsorship and naming rights sales, partnership activation, international business development, and premium sales existing within AEG Facilities, live events, sports franchises, and music properties. The division is responsible for over $500 million of gross sponsorship revenue and premium sales with an expected growth rate in the next several years.
Since joining AEG in 2005, Mr. Baker has quickly risen within the group from activation, managing such large partners as The Home Depot, AT&T and DirecTV, to the sales and business development side, becoming the youngest Vice President within the division. Responsible for the relationship with Amgen, title partner of AEG’s Amgen Tour of California cycling event, Mr. Baker has successfully negotiated and extended the multi-year entitlement agreement on two separate occasions.
Mr. Baker played point in securing the naming rights of two core AEG Facilities venues, the Valley View Casino Center (San Diego, California), BBVA Compass Stadium (Houston, Texas), as well as being a member of the executive team that finalized a global relationship with StubHub, which includes Naming Rights of StubHub Center (Carson, California) and exclusivity within AEG’s ticketing company, AXS.com. In April 2013, Mr. Baker directed AEG efforts in finalizing the naming rights agreement with Allianz for a venue in Sao Paulo, Brazil.
As of 2014, Mr. Baker currently oversees all revenue budgets and sales team management of AEG Sports Event & AEG Facilities in North & South America. In addition, he has played key roles in developing, negotiating and activating large scale global relationships for AEG Facilities, Sports Teams and Music Assets with companies such as ABM, MillerCoors, City National Bank, Corona, Samsung, Toshiba, Tyco, UnitedHealthCare, Waste Management and many more.
Jill Durovsik was a founding board member of the Wellness Community of Philadelphia (now Cancer Support Community Philadelphia) over 25 years ago and has served on its board in addition to serving as Chairwoman of the organization. Today, Jill serves on the board of the Cancer Support Community Headquarters and is Chairwoman of the organization’s newly established Research and Training Institute. Ms. Durovsik’s support and vision has been deeply inspired by family circumstance and has fueled her dedication to helping patients and families triumph over the threat of cancer in their daily lives.
After graduating Skidmore College, Ms. Durovsik entered the business world and spent the bulk of her career in financial services and building entrepreneurial companies. At Merrill Lynch she was responsible for developing marketing and financial products for worldwide distribution. Later, Ms. Durovsik founded Corporate Concierge Inc. and built it into a highly successful consumer services company.
Ms. Durovsik is a strong advocate of the arts and an involved community leader. She has been an Associates Board Member at the Philadelphia Museum of Art and a founder of the museum’s largest family program, dedicated to introducing children and families to our nation’s cultural endowment. Ms. Durovsik attended the Barnes Foundation art study program and is a member of the National Advisory Council of the Tang Teaching Museum at Skidmore College. Ms. Durovsik is currently pursuing a Master’s Degree in nonprofit leadership at University of Pennsylvania’s School of Social Policy and Practice.
Ms. Durovsik and her husband Tom, an entrepreneur and currently Chief Executive Officer of FreedomPay, Inc., have three children; Taylor, Paige and John; and reside in Villanova, Pennsylvania.
Senseonics, Inc., Chief Financial Officer
Don Elsey has served in executive finance positions for both privately and publicly held companies. He is currently Chief Financial Officer of Senseonics, Incorporated. Senseonics is developing the first fully implantable continuous glucose sensor designed for highly accurate, long-term wear. Previously, he served as the CFO of Regado Biosciences, a public biopharmaceutical company. He was the CFO of LifeCell, Inc., a private regenerative medicine company, from 2013-2014 and a Senior VP and CFO at Emergent BioSolutions, Inc., a public biopharmaceutical company, from 2005-2012.
Mr. Elsey also served as the Director of Finance and Administration at IGEN International, Inc., a public biotechnology company, and its successor BioVeris Corporation, from 2000 to 2005. He also served as Director of Finance at Applera and in several finance positions at IBM, Inc.
Mr. Elsey serves on the board of directors of RegeneRx Biopharmaceuticals, a public biopharmaceuticals company, as well as on the board of the Cancer Support Community. He received an MBA in finance and a BA in economics from Michigan State University.
Jeffrey A. Galvin
Jeffrey A. Galvin
American Gene Technologies™, CEO
Jeffrey A. Galvin is the CEO and Co-founder of American Gene Technologies™ (AGT). Mr. Galvin earned his BA degree in Economics from Harvard in 1981. Mr. Galvin has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. Mr. Galvin came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
AGT is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer, or HCC). Its drug candidates have achieved initial proof of concept in preclinical studies and have potential to deliver cost-effective therapies that are better targeted and more potent with fewer side effects. AGT’s drugs will treat symptomatic disease, but are intended to provide durable cures that extend the length and improve the quality of patients’ lives.
AGT anticipates becoming a clinical stage company in 2018 with a Phase I human trial for its HIV functional cure. AGT has three lead candidate drugs in its pipeline – all based on its proven drugdelivery platform — a proprietary vector with broad applicability in immuno-oncology and thousands of additional diseases.
David Hicks has been an executive in the information technology industry for 30 years. From 1995 - 2012, Mr. Hicks was a founder and Chief Information Officer at HealthGrades, the leading ratings company for healthcare providers. Mr. Hicks helped grow HealthGrades into the premier destination for consumers seeking information on doctors and hospitals, reaching nearly one million daily visitors across its online properties. The privately held firm was sold to Vestar Capital Partners in 2010.
Today, Mr. Hicks consults on web strategies for healthcare startups. Mr. Hicks received a BS degree in Management Information Systems from Colorado State University. Mr. Hicks served on the board of MyLifeLine.org Cancer Foundation for three years. Mr. Hicks enjoys golf, reading, hiking and spending time outdoors.
Avalere, Vice President, Reimbursement and Product Commercialization
Fauzea Hussain currently serves as the Vice President, Public Policy for McKesson. In this role, Fauzea works across the enterprise to ensure McKesson’s public policy strategy meets the diverse needs of McKesson’s comprehensive suite of solutions across the care continuum, while meeting the company’s mission of creating a sustainable healthcare environment that drives better health for all patients. She works across the business on issues impacting distributors and wholesalers, community providers, health systems, pharmacies, and most importantly patients. Fauzea is a seasoned policy expert with more than 20 years of experience in assessing the impact of state and federal policy and market changes on patient access, provider reimbursement and the life sciences industries. Prior to joining McKesson, Fauzea led Avalere’s Reimbursement and Market Access team, a well-recognized leader in developing and implementing innovative integrated market access strategies for drugs, biologics, devices and technologies across payers and settings. She has worked with the top global life sciences companies, a range of physician and non-physician provider groups as well as patient advocates.
Partner, DRG Consulting
John Jaeger, a Partner leading DRG Consulting’s US Market Access Practice, is a commercial strategy consultant with a strong track record of client service and US pricing, reimbursement, and market access expertise. In particular, John has a strong interest and focus in partnering with clients on the development and implementation of innovative segment-based engagement, successful market entry, and post-launch optimization.
For over 10 years, John has worked across the US healthcare landscape on a variety of topics including healthcare reform, product launch, portfolio and life-cycle management, pricing and contract strategy, and regional influence mapping. As part of DRG Consulting, John has supported a wide range of clients from top 10 pharma manufacturers to pre-clinical start-ups. While engaging a broad array of therapeutic areas, John has successfully executed over a dozen US and Globally focused market access engagements within the HIV therapeutic arena.
Outside of DRG Consulting, John has presented at multiple leading industry conferences regarding biosimilar commercial strategy and evolving benefit design structures. John is an adjunct professor for the University of Sciences MBA program and is a guest lecturer for the Rutgers MBA program. In addition, John serves on the Leadership Board for the Cancer Support Community’s Research and Training Institute.
John completed a MPA in Public Health at the University of Delaware and holds a BS in Public Administration from Shippensburg University
Shannon La Cava
Shannon La Cava
Cancer Support Community Los Angeles, Program Director
Shannon La Cava, PsyD started her role as Program Director with the Cancer Support Community Los Angeles in September 2015. Leading up to her current position, Ms. La Cava joined the American Cancer Society as a volunteer and advocate after caring for a close family member that was diagnosed with cancer. Ms. La Cava's work with Oncology patients and families inspired her continued education. Today, she is a licensed clinical psychologist who specializes in delivering supportive services to adult, children, and families diagnosed with cancer.
With nearly 20 years of experience in the healthcare industry, Ms. La Cava incorporates clinical experience with theoretical understanding to offer support, relief, and change to the families she supports. She received her MA in Psychology in 2008 from Pepperdine University and her Doctorate in Clinical Psychology from The Chicago School of Professional Psychology with clinical externships in the Hematology and Oncology Department of the Children’s Hospital Los Angeles and the Department of Family Medicine at UCLA. In 2014, she reported her research on Siblings of Pediatric Cancer Patients at the American Psychosocial Oncology Society's (APOS) convention in a podium presentation. She remains an active member of APOS, American Psychological Association (APA), and California Association of Marriage and Family Therapy (CAMFT).
Jing Liang is an entrepreneur and management consultant. He is the co-founder and managing partner of Umbrex, a global community of independent, top-tier management consultants. Mr. Liang also founded and serves as the CEO of Attenua, a biotech developing non-narcotic prescription treatments for chronic cough. Mr. Liang was a co-founder of Storelli Sports, the only brand devoted exclusively to the design and manufacture of head-to-toe soccer protection at every position. He holds a Ph.D. in Molecular Biophysics from Johns Hopkins University and a BS in Molecular Biology & Biochemistry from Penn State University.
Paula J. Malone, PhD
Paula J. Malone, PhD
Paula J. Malone, PhD, is Founder and President of Wings Foundation, Inc. She is a retired developmental/clinical psychologist, who first worked in hospital and clinic settings developing and running programs for families and children, neonates to adolescents. In private clinical practice, Dr. Malone developed a multi-disciplinary practice, Comprehensive Psychological Services, LLC, to serve the mental health of children, families and adults throughout Delaware and portions of Pennsylvania and New Jersey. She became involved with The Wellness Community Delaware (now Cancer Support Community Delaware), volunteering and ultimately becoming a Board Member. In 2004, Dr. Malone joined the National Board of The Wellness Community (now Cancer Support Community). In 2010, Dr. Malone and the Wings Foundation made a leadership gift to Cancer Support Community’s Research and Training Institute (RTI). Dr. Malone’s interest in supporting CSC, its affiliates and the RTI, stems not only from her previous professional involvement with cancer patients, but from personal issues as well: she has survived longer, cancer-free, than any other female for generations on both sides of her family and has been a caregiver to two who passed away. She has three children and three grandchildren. Dr. Malone is a licensed pilot and a certified scuba diver.
Jonathan T. Marks
Jonathan T. Marks
Baker Tilly’s Forensic and Litigation practice, Partner
Jonathan T. Marks, CPA, CFE and NACD Board Fellow, is a partner in Baker Tilly’s Forensic and Litigation practice. He has more than 30 years of experience working closely with his clients, their board, senior management, and law firms on global (cross-border) fraud and misconduct investigations, including bribery, corruption, and compliance matters.
Marks specializes in internal and regulatory investigations; governance matters; risk assessment, design and implementation of compliance programs; global fraud risk management programs; and compliance coordination and monitoring services for the private, public, not-for-profit sectors. He assists his clients in mitigating future potential issues by conducting root-cause analysis, developing remedial procedures, and designing or enhancing governance and compliance systems along with internal controls, policies and procedures, and customized training.
Marks is a well-regarded author and speaker, who has gained international recognition for developing thought leadership that has enhanced the profession. He presents regularly on an array of fraud, ethics, and forensic accounting topics. Marks was an adjunct professor at Rider University and today is a guest lecturer at Lehigh University. He has previously held leadership positions at a national accounting and a global disputes and investigations professional services firm.
Apex Health Innovations
Rich Mutell is an accomplished business executive, health economist, and application developer with over 25 years of experience in the biopharmaceutical and healthcare industry.
Prior to starting Apex Health Innovations, Mr. Mutell served as Head of the Health Economic Modeling and Medical Informatics and Technology group at DaVita Clinical Research. In this role, he built a team of scientific, medical, and technology experts to create innovative, mobile platform solutions for real-world data from clinical, market access, and health economic studies. Prior to joining DaVita Clinical Research, Mr. Mutell spent more than ten years at Amgen, the world's largest biotechnology company. He served in different positions of increasing responsibilities, including as a health economist for EPOGEN, one of the first commercially successful biologics. He also served as the Operations Director for the Global Health Economics, Global Pricing and Payer Planning, and International Health Economics teams. He specialized in developing and deploying multiple web-enabled applications to manage product value strategies, product budgets, project research portfolios, and strategic publication plans. Mr. Mutell began his career at Oracle and the Department of Defense (Health Affairs), where he built technical solutions for data assessment and analysis.
Mr. Mutell works extensively with social workers in the dialysis and transplantation setting and is an advocate for the impact and benefit social workers have on patient outcomes. His desire to volunteer with Cancer Support Community stems from a profound sense of loss of two close friends to cancer – and he saw first hand how a meaningful support structure helped them and their families fight this terrible disease.
Mr. Mutell served for 13 years in the United States Army and is a graduate of the Defense Language Institute. He holds a Master of Business Administration from Pepperdine University, a Master of Arts in Public Policy and Program Evaluation from the University of Nebraska, and a Bachelor of Arts in Political Science from California Polytechnic State University at San Luis Obispo
Lynne O’Brien (Secretary)
Lynne O’Brien (Secretary)
Lynne O’Brien worked as a Policy Analyst with the White House Cancer Moonshot office under former Vice President Joe Biden. Previously, she worked as director of the Washington Government Affairs Office of DuPont Merck and DuPont Pharmaceuticals, working with members of Congress on issues involving the U.S. Food and Drug Administration, tax legislation, and health care reform. She started her career in DC with Williams and Jensen, a lobbying/law firm in Washington, DC, focusing on health care clients. Ms. O’Brien is also on the national board of the Leukemia, Lymphoma Society (LLS) and is a trustee of The Potomac School in McLean, Virginia. Ms. O'Brien graduated cum laude from Princeton with an A.B. in political science and earned her law degree from Georgetown University Law Center. She is also a blood cancer survivor who finished treatment for chronic lymphocytic leukemia in 2016.
Michael M. Paese
Michael M. Paese
Goldman Sachs, Global Co-head, Office of Government Affairs
Michael Paese is global co-head of the Office of Government Affairs at Goldman Sachs. He joined the firm as a managing director in 2009. Prior to joining Goldman Sachs, Mr. Paese was executive vice president for Global Advocacy at the Securities Industry and Financial Markets Association (SIFMA), where he was responsible for global legal, governmental and legislative affairs and advocacy initiatives. Previously, he was Deputy Staff Director of the US House Financial Services Committee and he also had joint responsibility for Committee policy related to the banking, securities and insurance industries.
Earlier in his career, Mr. Paese worked at Mercantile Bankshares Corporation, where he held several senior positions, including executive vice president and chief administrative officer. Before joining Mercantile, he held the position of Senior Minority Counsel with the House Financial Services Committee. Mr. Paese has also held positions at JPMorgan Chase & Co. and was an associate at Davis Polk & Wardwell with the financial institutions practice.
Mr. Paese earned a BA from Notre Dame and a JD from Notre Dame Law School.
Andrew Sandler (Vice-Chair)
Andrew Sandler (Vice-Chair)
Treliant, LLC, Chairman
Andy Sandler is an entrepreneur, investor, and strategic advisor to the financial services industry. He leads Temerity Capital Partners, the Sandler family office and private investment company, which invests in and advises early-stage companies developing new technologies in financial services.
Mr. Sandler is founder and Chairman of Treliant Risk Advisors, the nation’s preeminent privately owned and operated financial services industry consulting firm; CEO and founder of Asurity Technologies, a software firm focused on providing automated compliance management solutions for the mortgage and banking industries; and founder of The Sandler Family Foundation, which focuses its philanthropic activities on supporting social entrepreneurship. He also founded and led Buckley Sandler, a premier financial services law firm.
For the past 30 years, Mr. Sandler has been a trusted strategic advisor to the financial services industry first as a Partner at Skadden and most recently as Chairman and Executive Partner of Buckley Sandler. Chambers USA has recognized Mr. Sandler as “one of the leading stars of the financial services regulatory firmament.” Legal Times named him as a “Legal Visionary” for his role in founding and leading Buckley Sandler and as “Deal Maker of the Year” for his regulatory advice in navigating complex transactions. Mr. Sandler was named a Public Justice Trial Lawyer of the Year finalist for his representation of the Navajo Nation in its breach of trust litigation with the United States where Mr. Sandler and his colleagues achieved a $554 million settlement for the Nation in 2014.
Mr. Sandler sits on the Board of Advisors of the American Association of Bank Directors and serves as the Vice Chair of the National Board of Directors of the Cancer Support Community, a global non-profit organization delivering psycho-social support to cancer patients and caregivers.
Mr. Sandler holds a JD and MBA degree from the University of Pennsylvania Law School and Wharton School of Business; an MA from the University of Warwick (U.K., Rotary Foundation Fellow), and a BA from Union College. He is a fellow in the American College of Consumer Financial Services Lawyers. His leadership roles at the American Bar Association Litigation and Business Law Sections have included Chair of the Consumer and Civil Rights Committee and Vice Chair of the Banking Law Committee.
Ken Scalet spent 17-years at Accenture, working largely in the health care industry on large-scale, technology enabled programs. As a partner, Mr. Scalet launched Accenture’s Federal Health practice. Following his retirement from Accenture in 2004, Mr. Scalet established an independent health IT consultancy. He has also channeled his professional energy toward board service for local and national not-for-profit organizations. He has served on the Board of Directors of Cancer Support Community since 2003 and serves as the chair of the Technology Committee. Mr. Scalet received a BA in economics from Franklin & Marshall College in 1987. He is married with 3 children and lives in Rockville, Maryland.
Charles R. Scheper
Charles R. Scheper
Bexion, Chairman of the Board
Chuck Scheper is the Chairman of the Board of Bexion Pharmaceuticals LLC, an emerging bio-tech company focused on the development and commercialization of innovative cures for cancer. He served as interim Mayor of Covington, Kentucky in 2012, and until his retirement in 2010, he served as the Chief Operating Officer at Great American Financial Resources, a $20 billion life and annuity company based in Cincinnati, Ohio.
Mr. Scheper has been involved with numerous volunteer efforts in the community over the years and currently he is the Chair of the Catalytic Development Funding Corp of Northern Kentucky, and he serves on the boards of Vision 2015, the Metropolitan Club and the Greater Cincinnati Foundation. He is also a member of the World President's Organization.
Mr. Scheper is a cancer survivor and his journey to wellness led him to become active in various causes related to cancer, including the Cancer Support Community, where he has served as the National Board Chairperson and currently is a board member. He is a graduate of Thomas More College, and he and his wife, Julie Geisen Scheper, live in the historic Licking Riverside neighborhood of Covington, KY.
President/CEO of the Cancer Support Community Central Ohio
Bev Soult has been the President/CEO of the Cancer Support Community Central Ohio for nearly 12 years. In her role Bev leads a team of individuals in strategic and programmatic growth that provides direct services with more than 80 monthly programs, so that no one faces cancer alone.
Prior to CSC, she has experience as VP of National Events and Partnership Development, and was the Executive Director of First Nights of Columbus and successfully led the organization to receiving top international awards.
She has been a member of the Ohio Partners for Cancer Control for nine years and currently serves as Chair. She previously served as Co-Chair for the 2015-2020 State Cancer Plan and served as Chair for Patient Centered Services, Clinical Trials and Research and Hospice and Palliative Care. She also currently serves as a board member on the Hospice of Central Ohio Board of Directors.
Bev has had a life-long commitment to volunteerism and making an impact in her community and state. Her greatest joy is her family. She has been married for 39 years and has three amazing sons, three daughters-in-law and two granddaughters!
Holly Tyson (Treasurer)
Holly Tyson (Treasurer)
Dick's Sporting Goods, Chief Human Resources Officer
Holly Tyson is the Chief Human Resources Officer at DICK’S Sporting Goods. In this role, which she has held since August 2016, Ms. Tyson is responsible for leading the overall talent strategy for DICK’S, while ensuring that its culture, practices, policies and operations align with the company’s overall values and objectives. Ms. Tyson also provides strategic human resources leadership to Dick’s executive management team, shareholders and board of directors.
Prior to joining DICK’S, Ms. Tyson served as the Chief Human Resources Officer at The Brink’s Company, a global leader in security-related services, including armored car transportation, money processing, long-distance transport of valuables, vaulting and other value-added solutions. Prior to Brink’s, she led the human resources function in the United States for Bristol-Myers Squibb, Co., including planning and management of current and future talent needs, organization design and development, performance management, and career and capability development.
Ms. Tyson began her career with Accenture (then Andersen Consulting) in their Change Management practice and then went on to hold varying leadership positions across industries and functions, including roles at CIGNA Corporation and leading an Organizational Development practice at Alliance Consulting.
Ms. Tyson holds a Master’s Degree in organizational psychology from Columbia University and a Bachelor’s Degrees in English and psychology from the College of William and Mary. She lives in Pittsburgh with her husband Jeff and their two sons.
Cancer Support Community, Chief Executive Office
Kim Thiboldeaux joined The Wellness Community in 2000 as President and Chief Executive Officer. In 2009, the headquarter offices of The Wellness Community and Gilda’s Club joined forces to become the Cancer Support Community, one of the largest providers of social and emotional support worldwide, where Kim has maintained her role as President and CEO. The combined organization is also likely the largest employer of psychosocial oncology mental health professionals, advancing the idea that psychosocial care is as important as medical care in the face of a cancer diagnosis. The Cancer Support Community provides social and emotional support through a network of nearly 50 local affiliates, more than 100 satellite locations and online at www.cancersupportcommunity.org. The organization also maintains a Research & Training Institute in Philadelphia, PA.
Formerly the Director of Patient Relations for Oncology & Transplant at Hoffmann-LaRoche, Inc., Kim brings to this position a wealth of experience in health care, patient education and national patient advocacy. Kim serves in numerous leadership roles in the cancer and health care communities including: founding board member of ENACCT (Education Network to Advance Cancer Clinical Trials), member of the American College of Surgeons Commission on Cancer, Co-Chair of the Alliance for Quality Psychosocial Care, and Advocacy Board Member of the Ruesch Center for the Cure of GI Cancers at Lombardi Comprehensive Cancer Center. Prior to joining Roche, she served as the Director of Corporate Relations at Whitman-Walker Clinic, a Washington, D.C.-based clinic that provides comprehensive services to people with HIV and AIDS.
Kim co-authored The Total Cancer Wellness Guide, which was published by BenBella Books on June 1, 2007. This timely book is a roadmap for all people affected by cancer and offers helpful tips on treatment decisions, side effect management, social and emotional issues and more. She is also the host of Frankly Speaking About Cancer with the Cancer Support Community, an award-winning Internet talk radio show that airs weekly on VoiceAmerica.com and is aimed at informing and inspiring listeners to live well with cancer.
Eli Lilly & Company, Senior Director of Global Advocacy and Professional Relations
Tom Wallace is the Senior Director of Global Advocacy and Professional Relations at Eli Lilly and Company. In addition, he is a member of the Global Corporate Affairs Leadership Team, which has responsibility for the Company’s public affairs function worldwide, led by the Senior V.P. of Corporate Affairs.
Mr. Wallace has led the company’s outreach to patient advocacy groups and health professional associations since 2002, expanding from leading the U.S. function to leading a global function in 2008. His role includes defining and managing how the company interacts with external organizations. The focus areas are gaining insight about what will improve innovation and meet patient’s needs, and building direct and virtual alliances through digital engagement to improve health care delivery and regulatory systems and public policies. Mr. Wallace has worked with Lilly executives to develop and implement several initiatives to improve transparency within the healthcare field, and to establish principles for interactions with external organizations. In several cases Lilly is credited with setting the trend for Industry transformation.
Employed by Lilly since 1989, Mr. Wallace’s roles have included those in state government relations, new product planning and sales. Prior to joining Lilly, he served as the Assistant Director of the State of Indiana Washington, D.C. Office under Governor Robert D. Orr. He was selected for the Governor’s Fellowship program, a state program modeled after the White House Fellows program. Mr. Wallace is a graduate of Butler University and holds a Masters of Public Affairs degree from Indiana University.
Mr. Wallace serves on several advisory boards and was chairman of the PhRMA Alliance Section from 2006 to 2008, during a time of great change to the U.S. Medicare Part D prescription drug benefit. He has been an active participant about broader health care reforms. He is on the national boards of the National Health Council and Cancer Support Community. Other engagements have included speaking roles at the “Coach K Leadership Institute” at Duke University and participating in the Wharton-Lilly Leadership Program for nonprofit health care executives at the University of Pennsylvania.
Mr. Wallace lives in the Washington, D.C. area; he and his wife Lynn have two college age sons.
Ogilvy CommonHealth Payer Marketing, President
Michael Zilligen is a seasoned marketing leader in the pharmaceutical and device marketplace, with 25 years of health care marketing, medical education, managed markets strategy and professional promotion expertise. He is responsible for all operations at Specialty Marketing focused on oncology, virology, medical device and rare diseases. Prior to assuming leadership at Ogilvy CommonHealth Specialty Marketing, he was President of ProCom where he repositioned the group from CME to promotional medical education.
Previously, Mr. Zilligen was a SVP with Ogilvy Payer Marketing providing managed markets strategic guidance to health care clients. He was responsible for reimbursement strategy, developing managed care marketing solutions across customer segments that assist clients in improving or protecting formulary access and pulling through reimbursement advantages to drive incremental sales.
Prior to joining OCH Payer Marketing, Mr. Zilligen was Group Director of Marketing for the Interventional Cardiology and Radiology portfolio of products at B. Braun Medical, a leader in medical devices. This included responsibility for global brand and franchise strategic planning, professional promotion, new product development and educational programming. Before his tenure in the device industry, Mr. Zilligen spent five years with Marion Merrell Dow in institutional sales & managed care account management. His expertise includes domestic and international product management, new product introductions, hospital strategy, and specialty markets. He has a unique skill set consisting of professional promotion, medical education, product marketing and managed care – acquired during positions of increasing responsibility.